Kits
Biologic therapy monitoring: IDKmonitor® Golimumab drug level, ELISA
Kits
Description
The IDKmonitor® Golimumab Drug Level ELISA is intended for the quantitative determination of free golimumab in EDTA plasma and serum.
Tumor Necrosis Factor alpha (TNFα) belongs to the proinflammatory cytokines,
which promote and sustain inflammatory reactions. It is produced by macrophages
and T cells and plays a central role in both acute and chronic inflammations. Consequently,
chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid
arthritis, or psoriasis are increasingly being treated with antibodies against
TNFa, which target directly the underlying inflammatory processes.
The clinical efficacy of an anti-TNFa therapy usually correlates with the trough level
of the therapeutic antibody, meaning the drug level just before the next application
of the anti-TNFa antibody. Several factors influence the trough level, among them
dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics
and immune reaction (formation of anti-drug antibodies, ADA) [1, 2].
It is thought that ADA functionally neutralise the therapeutic antibodies or induce
their rapid elimination. Consequences of ADA formation can be therapy failure and
allergic reactions during anti-TNFα antibody application [1, 3].
The IDKmonitor® golimumab drug level ELISA for the determination of free golimumab
(e.g. SIMPONI®) measures reliably the effective drug concentration and is an
opportunity for the treating physician to monitor and optimise the therapy early on.
Tumor Necrosis Factor alpha (TNFα) belongs to the proinflammatory cytokines,
which promote and sustain inflammatory reactions. It is produced by macrophages
and T cells and plays a central role in both acute and chronic inflammations. Consequently,
chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid
arthritis, or psoriasis are increasingly being treated with antibodies against
TNFa, which target directly the underlying inflammatory processes.
The clinical efficacy of an anti-TNFa therapy usually correlates with the trough level
of the therapeutic antibody, meaning the drug level just before the next application
of the anti-TNFa antibody. Several factors influence the trough level, among them
dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics
and immune reaction (formation of anti-drug antibodies, ADA) [1, 2].
It is thought that ADA functionally neutralise the therapeutic antibodies or induce
their rapid elimination. Consequences of ADA formation can be therapy failure and
allergic reactions during anti-TNFα antibody application [1, 3].
The IDKmonitor® golimumab drug level ELISA for the determination of free golimumab
(e.g. SIMPONI®) measures reliably the effective drug concentration and is an
opportunity for the treating physician to monitor and optimise the therapy early on.